CrushSCI.com
246.2Average days
212Median days
77Fastest days
791Longest days
342025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

258 days

The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant

Authors
Joseph E. Rower; Tia S. Freeman; Cassandra E. Deering-Rice; Kimberly M. MolinaShow moreShow less
Affiliations
1. Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, USA; 2. Center for Human Toxicology, University of Utah College of Pharmacy, Salt Lake City, USA; 3. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, USA; 4. Primary Children’s Medical Center, Intermountain Healthcare, Salt Lake City, USA; 5. Division of Cardiology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, USA; 6. Department of Pediatrics, Dartmouth Hitchcock Medical Center, Lebanon, USAShow moreShow less
Source PDF DOI Publisher page
131 days

Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants

Authors
Amy L. Pasternak; William Tackett; Mousumi Banerjee; Simi Paul; Emily Bertucci-Richter; Xiang Zhou; Vaibhav Sahai; Daniel L. HertzShow moreShow less
Affiliations
1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, USA; 2. Department of Pharmacy, University of Michigan Health, Ann Arbor, USA; 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, USA; 4. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USAShow moreShow less
Source PDF DOI Publisher page
214 days

Bridging the pharmacogenomics gap: a survey of healthcare workers in South-Western Nigeria

Authors
Ochuko M. Orherhe; Omolabake F. Ayodele; Jeremiah O. Omojuyigbe; Ayodapo O. Jegede; Olumide A. Alade; Kikelomo Oladimeji; Oluwatimilehin S. Ogunde; Promise U. Okereke; Oluwafemi O. Agboola; Moteehat O. Olu-Lawal; Olusanya Aluko; Babatunde A. Adeagbo; Oluseye O. BolajiShow moreShow less
Affiliations
1. Department of Clinical Pharmacy and Pharmacy Administration, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 2. Department of Pharmacology, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 3. Department of Nursing, General Hospital, Ifako Ijaiye, Nigeria; 4. Department of Dentistry, Faculty of Dentistry, Obafemi Awolowo University, Ile-Ife, Nigeria; 5. Department of Dentistry, College of Medicine, University College Hospital, Ibadan, Nigeria; 6. Department of Public Health, Ministry of Health, Osogbo, Nigeria; 7. Osun State Hospital Management Board, Osogbo, Nigeria; 8. Department of Pharmacy, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria; 9. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, NigeriaShow moreShow less
Source PDF DOI Publisher page
791 days

The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine

Authors
Najmeh Ahangari; Mohammad Doosti; Mojtaba Safi; Narges Hashemi; Shima Imannezhad; Bita Barazandeh; Ehsan Ghayoor Karimiani; Mehran Beiraghi ToosiShow moreShow less
Affiliations
1. Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 2. Rare Pediatric Neurological Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 3. Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran; 4. 7 Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK, Institute of Neurology, London, UKShow moreShow less
Source PDF DOI Publisher page
160 days

Risk of drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele

Authors
Jeong-Hoon Han; Raúl J. Andrade; Einar Stefán Björnsson; James Hendricks Lewis; M. Isabel Lucena; Suyoung Go; Simona Stankeviciute; Guruprasad P. Aithal; Kyuchan Kim; Chong Sik Lee; Carrolee Barlow; Eunhee KimShow moreShow less
Affiliations
1. Kainos Medicine, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea; 2. Department of Medicine and Gastroenterology Service, IBIMA-Plataforma Bionand, Hospital Universitario Virgen de la Victoria, University of Málaga, Málaga, Spain; 3. Centro de Investigación en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; 4. Department of Internal Medicine, Landspitali University Hospital, University of Iceland, Reykjavík, Iceland; 5. Faculty of Medicine, University of Iceland, Reykjavík, Iceland; 6. Division of Gastroenterology, Department of Medicine, Georgetown University, Washington, USA; 7. Servicio de Farmacología Clínica, IBIMA-Plataforma Bionand, Hospital Universitario Virgen de la Victoria, University of Málaga, Málaga, Spain; 8. Regulatory Consulting, Parexel International, 2520 Meridian Parkway, Durham, USA; 9. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, and the University of Nottingham, Nottingham, UK; 10. Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Republic of KoreaShow moreShow less
Source PDF DOI Publisher page
127 days

Barriers and facilitators to the implementation of pharmacogenomic testing for antidepressants use in primary care: a systematic review using the consolidated framework for implementation research

Authors
Muireann Counihan; Deirdre Cushen; Sookyung Kwak; Amy Allen; Donnchadh Fitzsimons Mac Giolla Chuda; Weronika Romanska; Ibrahim Nakchbandi; Rose Reynolds; Chad Bousman; Mark Ledwidge; Joseph Gallagher; Cristín RyanShow moreShow less
Affiliations
1. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland; 2. Department of Medical Genetics, University of Calgary, Calgary, Canada; 3. School of Medicine, University College Dublin, Belfield, IrelandShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does PHARMACOGENOMICS JOURNAL take to review a manuscript?

As of 2026-11-19, CrushSCI has 15 complete review records for PHARMACOGENOMICS JOURNAL. The fastest paper went from submission to acceptance in 77 days (Effects of CYP3A4, CYP3A5 , and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation, received 2026-05-06, accepted 2026-07-22); the slowest took 791 days. The average is 246.2 days and the median is 212 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.